Provider update

Prior authorization requirement change for Part B drug:
Bavencio (avelumab)

Summary of change: On October 1, 2017, Amerigroup Amerivantage (Medicare Advantage) prior authorization (PA) requirements will change for Bavencio (avelumab). Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage.

Noncompliance with new requirements may result in denied claims. PA requirement will be added to the following code:

- **Bavencio** (avelumab): For the treatment of metastatic Merkel cell carcinoma (MCC) in adults and pediatric patients 12 years and older. (J9999) (unlisted, no J code established at this time)

Not all PA requirements are listed here. Detailed PA requirements are available to contracted providers by accessing the Provider Self-Service Tool within Availity. Noncontracted providers should contact Amerigroup.

The information in this update may be an update or change to your provider manual. Find the most current manual at https://providers.amerigroup.com.

In New Mexico, Amerigroup Community Care of New Mexico, Inc. In Texas, Amerigroup members in the Medicaid Rural Service Area are served by Amerigroup Insurance Company; all other Amerigroup members are served by Amerigroup Texas, Inc. In Washington, Amerigroup Washington, Inc.

Amerivantage is a D-SNP plan with a Medicare contract and a contract with the State Medicaid program. Enrollment in Amerivantage depends on contract renewal.

In New Mexico: Amerigroup Community Care of New Mexico, Inc. is an HMO plan with a Medicare contract. Enrollment in Amerivantage Classic depends on contract renewal.